Latest Market News

GCM Corporation has launched its first Very High Density (VHD) heat sink product line, marking a pivotal step from development to commercial sales in thermal management technology.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Enlitic has landed a US$1.2 million contract to migrate and standardise millions of medical imaging records for Parkland Health, marking its third major US healthcare win this month.

Since its October 2025 ASX IPO, Temas Resources has made significant strides in commercialising its proprietary metallurgical technology and advancing its Québec mineral projects, supported by solid financial reserves.

The Australian Treasurer has issued interim directions preventing Hong Kong Ying Tak Limited from transferring or voting over 361 million shares in Northern Minerals, amid suspected breaches of foreign investment disposal orders. Northern Minerals is cooperating with regulators while focusing on its rare earths project.

Globe Metals & Mining’s 2026 Bankable Feasibility Study for the Kanyika Niobium Project in Malawi confirms robust economics, a 24-year mine life, and a strategic phased development approach.

POSCO Holdings has postponed its investment decision on Anson Resources’ Green River lithium demonstration plant due to global uncertainties, yet maintains strong collaboration and strategic commitment.

Prospect Resources has confirmed a continuous near-surface copper sulphide system over more than 1km at its West Mwombezhi prospect in Zambia, with a maiden resource estimate due in Q2 2026.

Japan Fluorite Corporation has completed its second $5 million tranche investment in the Speewah Fluorite Project, advancing the feasibility study for Australia's first acidgrade fluorspar operation.

The Star Entertainment Group has completed the first stage of its exit from the Destination Brisbane Consortium, locking in a fixed $18 million annual operator fee and shedding a major debt guarantee.

Actinogen Medical has initiated the open-label extension of its XanaMIA Alzheimer’s trial, offering all participants active Xanamem treatment for up to 25 months to gather long-term safety and efficacy data ahead of final trial results.